Navigation Links
Study Compares Risk With Two Diabetes Drugs
Date:8/24/2010

217 patients taking rosiglitazone and 217 taking pioglitazone.

The study included 36,628 patients who had submitted insurance claims to WellPoint affiliates for either of the two diabetes medications between 2001 and 2005. Patients' average age was 54, and 58 percent were male. Wertz and her team obtained death records from the National Death Index, a central database administered by the National Center for Health Statistics.

The investigators divided patients into two equal groups, one receiving rosiglitazone and the other, pioglitazone. After adjusting the data for (removing/minimizing the effect of) age, gender, prior heart and blood vessel diseases and diabetes-related complications and severity indicators, they compared the incidence of heart attack, heart failure and death for an average 14 months of treatment and 19 months of post-treatment follow-up.

Diabetes is a disease in which the body cannot adequately produce the hormone insulin or uses it improperly. The disease can cause a potentially dangerous buildup of sugar in the blood and also increases the risk of heart and blood vessel diseases, which are the main causes of death for people with diabetes.

Rosiglitazone, sold under the trade name Avandia by GlaxoSmithKline, and pioglitazone, sold as Actos by Takeda Pharmaceuticals, belong to the same class of drugs, called TZDs or thiazolidinediones. They help the body use insulin more effectively by boosting the body's sensitivity to the hormone and thus help control blood sugar.

This study has results different from earlier ones that found a greater risk of heart attack among rosiglitazone users compared to patients on other treatments or placebo. In 2007, the Food and Drug Administration decided that the benefits of rosiglitazone outweighed the risks, and it remained on the market although its use decreased significantly. In July 2010, an FDA advisory committee again reviewed numerous studies, including this s
'/>"/>

SOURCE American Heart Association
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... EASTON, Mass. , Sept. 19, 2014 /PRNewswire/ ... "Company") today announced it has received and approved ... Barozyme HT48 instruments and has begun to manufacture ... the first instrument will be ready for shipment ... be built and released at a rate of ...
(Date:9/19/2014)... -- Aufgrund der enormen Nachfrage seines ... aktualisiert, der jetzt auch die Jahre 2014 - ... pharmaserialisation.com , zeigt die Serialisierungsanforderungen weltweit und den ... Für international tätige Unternehmen geht es ... sondern darum, "wann" sie die neu in Kraft ...
(Date:9/19/2014)... CAMBRIDGE, Mass. , Sept. 19, 2014   ... of advanced cancer genome analysis and testing services, ... discovering and developing highly selective kinase inhibitors for ... genomic study of malignant mixed Mullerian tumors (MMMT), ... reproductive system, also known as carcinosarcoma. The new ...
Breaking Medicine Technology:Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
(Date:9/20/2014)... Traditionally dentists have advised their patients against ... Dentistry is re-visiting that advice and changing his stance ... and wine have on oral health. “There’s good news and ... may be beneficial in protecting against gum disease, and red ... on coffee was from the September 2014 issue of ...
(Date:9/20/2014)... 20, 2014 QueenBeeTickets.com is ready to ... tour performances. She will visit many cities in North ... the 16th of April. , Click Here ... tickets at QueenBeeTickets.com. , The star’s fans are not ... their favorite young singer in a live performance. Ariana ...
(Date:9/20/2014)... “Motherhood is a wonderful gift and a huge responsibility,” says ... , “We know that you want to care for your ... to do as well.” , The article explains to new ... Family Physicians who practice obstetrics while pregnant, during delivery, and ... learn more about Community Health Center of Snohomish County and ...
(Date:9/19/2014)... “Copay coupons,” a drug manufacturer marketing tactic ... patients with prescription drug coverage, may now be infiltrating ... from the Department of Health and Human Services ... prohibit suppliers from offering side-payments to increase sales of ... The report highlights that two recent surveys, including one ...
(Date:9/19/2014)... September 19, 2014 On September 16, ... the Platinum PR and Top Places to Work in ... York City. Camino received honorable mentions in two categories ... for its work elevating Latina voices in the media. ... and be a part of its efforts to improve ...
Breaking Medicine News(10 mins):Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 2Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 3Health News:Discount Ariana Grande Tickets: QueenBeeTickets.com Delights Fans with Discount Concert Tickets for Ariana Grande’s 2015 Honeymoon Tour 2Health News:Newest Article from Community Health Center of Snohomish County Highlights The Importance of Proper Health Care for Expectant Mothers 2Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2Health News:Camino Public Relations Honored for Raising Latina Voices in National Health Care, Immigration Debates 2
... transform your medical center, and recharge your organization? A ... Future," may hold the key to revitalization. It will be ... President and CEO Nancy Schlichting will share her radical, but ... wisdom of her top executives in an interactive session on ...
... Illinois have identified a potential drug target for the ... in the membrane of neurons and other cells. ... receptor, sparking increased activity in the affected neurons, eventually ... findings appear in the FASEB Journal . ...
... Columbia University,s Mailman School of Public Health today announced ... the Frank A. Calderone Prize to Susan P. ... close to five decades has been instrumental in bringing the ... public policy. Professor Baker, an epidemiologist and licensed ...
... ... a percentage of fees from new clients to World Vision Canada on April 26th and ... (PRWEB) ... , is hoping to raise thousands of dollars for vulnerable people around the world while ...
... Supporting healthy ... ... in the care for mothers and infants, Brigham and Women’s Hospital (BWH) announces the launch ... healthy moms, pregnancies and babies. The Stork Fund will raise funds for clinical care, ...
... ... Dr. Oscar Ramirez, facial implants counteract this phenomenon and offer hope to those with facial ... (PRWEB) April ... belief that superficial matters such as beauty pale in comparison with deeper values such as ...
Cached Medicine News:Health News:Henry Ford Health System goes radical: Creating the hospital of the future 2Health News:Team finds promising new drug target for Alzheimer's disease 2Health News:Team finds promising new drug target for Alzheimer's disease 3Health News:Highest prize in public health -- the Frank A. Calderone Prize -- to Susan Baker, pioneer 2Health News:Tax Return Appointment Fees to be Donated to Charity by Tax Team Canada 2Health News:Brigham and Women's Hospital Launches Stork Fund 2Health News:Brigham and Women's Hospital Launches Stork Fund 3Health News:Boca Raton Plastic Surgeon's New Facial Implants Counteract Facial Aging 2Health News:Boca Raton Plastic Surgeon's New Facial Implants Counteract Facial Aging 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: